tert-butyl 4-((bromomethyl)sulfonyl)piperazine-1-carboxylate

Catalog No.: 
ACYZEH415
CAS No.: 
1443979-93-8
Molecular Formula: 
C10H19BrN2O4S
Molecular Weight: 
343.24
tert-butyl 4-((bromomethyl)sulfonyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$104.00InquiryInquiry
250mg98%$140.00InquiryInquiry
1g98%$352.00InquiryInquiry
5g98%$1077.00InquiryInquiry
10g98%$1597.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 4-((bromomethyl)sulfonyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-((bromomethyl)sulfonyl)piperazine-1-carboxylate
MDL No.MFCD24842749
Molecular FormulaC10H19BrN2O4S
Molecular Weight343.24
SMILESCC(C)(C)OC(=O)N1CCN(S(=O)(=O)CBr)CC1
InChI KeyLVUKARQJVGPWEM-UHFFFAOYSA-N
Synonymtert-butyl 4-bromomethanesulfonylpiperazine-1-carboxylate
CAS No.1443979-93-8

Synthetic Route by SureRoute

1. ACYZEH415 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7In Stock
  2. Plus
  3. ACBILC579 route compound structure diagram
    ACBILC57910099-08-8In Stock
  4. Then
  5. ACYZEH415 route product structure diagram
    ACYZEH4151443979-93-8
Inquiry

2. ACYZEH415 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7In Stock
  2. Plus
  3. ACPNXU123 route compound structure diagram
    ACPNXU12334239-78-6In Stock
  4. Then
  5. ACYZEH415 route product structure diagram
    ACYZEH4151443979-93-8
Inquiry

3. ACYZEH415 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYZEH415 route product structure diagram
    ACYZEH4151443979-93-8
Inquiry

Comments (0)